Introduction:

The UK exosome delivery platform is open to global collaboration, focusing on exosome loading and delivery for RNA, protein, gene therapy, and gene editing payloads, with a focus on licensing-in and joint development of preclinical technical assets such as exosome loading technology, manufacturing processes, subgroup screening, and early functional validation.

---

1. Buyer Information

: A British exosome delivery platform company with long-term expertise in cell technology, exosome engineering, and translational development. The company’s core competencies focus on EV/exosome delivery platforms based on stem/progenitor cell sources, with an emphasis on exploring the application of exosomes in RNA, protein, gene therapy, and gene editing-related payload delivery.

2. Assets

Sought Focus on exploring exosome delivery technologies and platform-based cooperation opportunities, with directions including but not limited to RNA/oligonucleotides, proteins, Exosome loading technologies for gene therapy or gene editing-related payloads, as well as EV/exosome manufacturing processes, separation and purification, subgroup identification, and effective subgroup enrichment technologies.
Projects do not require existing clinical assets; technologies with early in vitro validation, in vivo distribution, or functional data delivery are all communicable.

3. Financing and Operational Foundation

The company has supported R&D through open markets, government research projects, and industry cooperation, and has established capabilities related to exosome production, purification, loading, analysis, and in vivo functional validation.
Currently, the company adopts an operational model driven by platform cooperation and technology validation, continuously expanding exosome delivery and manufacturing capabilities through external collaborations.

4. Buyer Strength and BD Experience

The company has cross-border licensing, paid research, and joint development experience, having completed regional licensing for cell therapy projects with potential values exceeding £20 million. It also collaborates with global pharmaceutical companies to validate paid exosome delivery.
Recently, the company has collaborated with UK biotechnology companies and universities on miRNA gene regulation, exosome tissue trophies, loading, key quality attributes, and effective subpopulations, laying the foundation for BD and project execution to promote platform evaluation, co-development, and technology licensing.

5. Cooperation Model

The cooperation model is based on platform evaluation, research collaboration, Mainly co-development or option-to-license.
Buyers can provide capabilities in exosome production, loading, characterization, and functional validation. External projects can be developed collaboratively around load loading, delivery efficiency, manufacturing processes, subgroup screening, or specific application scenarios; If early validation results are positive, further licensing or specific project collaborations can be advanced.

---

In the global exosome delivery sector, platform companies are rapidly increasing demand for loading technologies, manufacturing processes, and targeted delivery validation.

The following section systematically reviews the current status and trends of the exosome delivery track from a track overview, scientific logic, technical routes, industry structure, business logic, to asset screening criteria, helping innovative asset holders and industry partners establish a clearer connection framework.

Sensory exosome delivery platform: From natural cell messengers to engineerable drug carriers

---

(1) Track Overview: Exosomes are transforming from biological phenomena into drug development platforms

Exosomes belong to the extracellular vesicles (EVs) system released by cells. They are encapsulated in a lipid bilayer and can carry proteins, lipids, mRNA, microRNA, and other nucleic acids, transmitting biological signals between cells. Strictly speaking, the term “exosome” should only be used when the origin of endosomal pathways has been fully proven; For formulations whose biological pathways have not yet been clearly determined, the International Society of Extracellular Vesicles (ISEV) recommends using operational terms such as “small extracellular vesicles.” This naming difference is not an academic detail but directly affects product characterization, mechanism explanation, quality control, and regulatory communication.
In drug development, exosomes are mainly advancing along two routes.

• The first is to use naturally secreted vesicles as active drugs, whose efficacy comes from the combination of proteins, lipids, and nucleic acids carried by exosomes themselves, commonly used in tissue repair, inflammation regulation, and regenerative medicine.
• The second is to use exosomes as delivery carriers, delivering siRNA, mRNA, antisense oligonucleotides, proteins, small molecules, and even gene-editing components into target tissues through engineered cell production, surface modification, or exogenous loading.

The two routes differ in their mechanisms of action, release standards, and clinical development pathways; True platform-based trading opportunities are more concentrated in the latter. Exosomes have gained attention due to the rapid development of RNA drugs, gene regulation, and protein replacement therapies. A large number of candidate molecules are active in vitro but are limited by in vivo stability, cell uptake, endosome escape, and tissue selectivity. Lipid nanoparticles have already validated the industrial value of nucleic acid delivery, but extrahepatic delivery, repeated drug administration tolerance, and effective exposure of certain tissues remain significant challenges. Exosomes offer an alternative pathway of biological origin: their membrane structure can protect the load, and the membrane proteins and lipid compositions formed by different mother cells may confer specific tissue philophiles, offering opportunities to further enhance targeting through engineering.

---

(2) Scientific Logic: Cell origin, payload loading, and tissue targeting jointly determine platform value
Exosomes are not standardized nanoparticles regardless of origin. Mesenchymal matrix cells, neural stem/progenitor cells, dendritic cells, immune cells, platelets, and vesicles produced by engineered stable cell lines may differ in membrane proteins, lipid composition, endogenous RNA, and in vivo distribution. The mother cell source affects both the natural function of exosomes and production stability, potential tumorigenic or immune risks, and process scale-up. Therefore, the platform’s core asset is often not a single batch of exosomes, but a production cell system with a clear source, stable genetic background, capable of building a master cell bank, and capable of continuous scaling.
Load loading can be divided into internal and external loading.
Endogenous loading involves expressing target RNA or proteins in production cells and using the cells’ own vesicle formation mechanisms to complete encapsulation; The advantage is that loading synchronizes with exosome formation, but requires control of expression stability, cellular stress, and endogenous impurities.
Exogenous loading involves adding drugs after vesicle separation through incubation, electroporation, ultrasound, extrusion, membrane permeability, or chemical ligation, offering a wider range of adaptations but prone to free load residue, vesicle aggregation, membrane damage, and inter-batch differences. Judging the quality of a platform cannot be judged solely by “how much is included,” but also by proving that the load is located inside the vesicle or stably bound to the membrane and maintains function after being released in the target cell.
Targeted strategies typically consist of three layers.

• The first layer utilizes natural tissue philophilies derived from mother cells;
• The second layer uses genetic engineering to display ligands, antibody fragments, or receptor-binding domains on the exosome membrane;
• The third layer is modified after separation using lipid insertion and chemical coupling.

Ultimate value should be demonstrated by in vivo data, including post-administration organ distribution, target cell uptake, exposure to non-target tissues, release of pharmacodynamic load, and dose-effect relationships. Fluorescence imaging or in vitro uptake enhancement alone is not enough to prove true functional delivery.

---

(3) Technical Route: The industrialization challenges of the “preparable” to “definable, scalable, and releasing
” exosome platforms focus on four stages: production, purification, analysis, and efficacy.
On the production side, it is necessary to establish repeatable culture systems in cell factories or bioreactors to control the source of the medium, cell subtitles, culture status, and harvest window.
The purification end often employs a combination of differential centrifugation, ultrafiltration/tangential flow filtration, dimensional rejection chromatography, ion exchange, or affinity capture, balancing yield, purity, shear damage, and scale-up cost. Single-laboratory methods are often difficult to directly translate into GMP processes.
Analyzing representations requires answering “how many, what it is, whether it is consistent, and whether it is effective.”
Common indicators include particle size and particle concentration, morphology, membrane protein markers, cell-derived features, protein/nucleic acid impurities, residual DNA, sterility, endotoxins, mycoplasma, loading content, and free load ratio. The ISEV MISEV2023 emphasizes the use of complementary methods to describe EV sources, separation processes, and characteristics, rather than relying on a few traditional markers to simply identify products. For drug development, it is also necessary to link key quality attributes with mechanisms of action and establish efficacy tests that can predict in vivo function.
Storage and formulation are also often underestimated thresholds. Exosomes may accumulate, break, or lose activity during freeze-thaw, concentration, filtration, and long-term storage. Developers need to determine buffer systems, freeze or freeze-drying conditions, container compatibility, transport temperature, and usage stability. Only when a closed loop is formed in cell banks, upstream processes, downstream purification, analytical methods, and formulation stability can platforms lay the foundation for moving from research collaboration to IND support and commercial licensing.

---

(4) Drug and Industry Landscape: Clinical validation has begun, but platforms are still in the early phase of phase-out

The current exosome drug pipeline spans oncology, neurological diseases, inflammation and immunity, respiratory, infection, and tissue repair. In clinical projects, the number of natural or cell-derived EV formulations exceeds that of truly engineered payload delivery products; Many studies remain investigator-initiated, small-sample, or early safety exploration. A 2025 review of MSC-derived EV/exosome studies from 2014 to 2024 screened 66 eligible clinical trials, reflecting increased clinical activity in this field, but dosage, formulation definition, endpoints, and reporting quality remain inconsistent.
On the industry side, three types of companies have formed:

• First, developing natural EV drugs derived from MSCs, platelets, or nerve cells, relying on exosomes’ own anti-inflammatory, repair, and regenerative effects;
• second, delivering RNA, proteins, and gene editing components through cell engineering, membrane protein display, or exogenous loading;
• Third, infrastructure companies that provide production, purification, and analytical capabilities. The most advanced clinical phase projects mainly fall into the first category, while truly engineered delivery products are still concentrated in Phase I or preclinical stages.

4.1 Natural EV Drugs: Leading in Clinical Stage, Focusing on Validating Safety, Dosage, and Compound Activity
Direct Biologics’ ExoFlo is an extracellular signaling agent derived from bone marrow MSCs, containing EVs and various soluble factors. The global EXTINGUISH ARDS study has entered Phase III, with plans to evaluate mortality and respiratory support-related endpoints in moderate to severe ARDS patients. This project represents a clinical frontier for the natural secretome pathway, but its active ingredient is not a single engineered exosome and cannot directly demonstrate the effectiveness of exosomes as payload delivery tools. RION is developing local regeneration products using the platelet-derived purified exosome platform PEP, with the Phase IIa study of PEP-TISSEEL for diabetic foot ulcers scheduled to be enrolled in 2025; Its development logic is to combine platelets’ natural repair signals with fibrin blockers, focusing on wound closure and tissue repair.
Aegle Therapeutics’ AGLE-102 uses donor MSC-derived EV for the topically treatment of latent dystrophic epidermolysis bullosa. The Phase I/IIa study has completed primary enrollment and continues follow-up, while expanding the scope of severe burn scenarios. EXO Biologics’ EXOB-001, targeting bronchopulmonary dysplasia in premature infants and using endotracheal MSC exosomes, has completed its first dose cohort in adaptive Phase I/II studies.
Brexogen’s BRE-AD01 uses stem cell-derived exosomes stimulated under specific conditions to treat moderate to severe atopic dermatitis; The US Phase I project disclosed mid-term progress related to mechanisms and security in 2026. These projects collectively demonstrate that natural EV drugs have begun entering disease-specific clinical validation, but product efficacy often comes from complex, multi-component bioactivity, with batch consistency and mechanism explainability remaining core challenges.

4.2 Engineered Delivery: Clinical validation is just beginning, with value focused on functional load release
ILIAS Biologics’ ILB-202 is currently one of the most representative engineered exosome drugs. Its EXPLOR platform delivers anti-inflammatory proteins into exosomes within production cells, intended for acute kidney injury related to cardiac surgery; Randomized, double-blind, placebo-controlled Phase I results from healthy volunteers are scheduled for publication in 2025, showing overall safety and good tolerability at test doses. The company plans to advance follow-up patient studies in the second half of 2026. The significance of this project lies in the fact that, for the first time, a relatively complete human evidence chain has been established in engineered protein loading, systemic drug delivery, and clinical-grade manufacturing, but efficacy still requires patient trial confirmation.
Evox Therapeutics focuses on rare diseases and the central nervous system with engineered exosome delivery proteins, RNA, and gene editing components. In 2026, the company will collaborate with the Rett Syndrome Patient Foundation to evaluate ExoEdit gene editing delivery, continuing its model of allocating resources from the Disease Foundation and pharmaceutical companies to early target validation. Aruna Bio’s AB126 is derived from neural stem cell exosomes, focusing on trans-blood-brain barrier regulation and neuroinflammation regulation, and is currently in the preclinical and IND support stages.
NurExone’s ExoPTEN delivers PTEN via intranasal delivery of exosomes to regulate siRNA for acute spinal cord injury, with ongoing advancement of CMC, U.S. manufacturing systems, and first-person human studies preparation from 2025 to 2026. Capricor’s StealthX is also positioned for nucleic acid, protein, and vaccine antigen delivery, but remains a preclinical platform; Its late-stage asset, deramiocel, is a cell therapy and should not be mistakenly classified as an exosome drug.
Codiak is the most important negative example in this field. Its engEx platform once promoted exoIL-12, exoSTING, and exoASO-STAT6 into Phase I oncology and collaborated with Sarepta to explore gene therapy, gene editing, and RNA payloads, but the company entered Chapter 11 in 2023, with related projects terminated or disposed of. This incident does not deny exosome delivery itself, but it shows that after entering the human body, platforms still need to demonstrate clinical differentiation, sustainable manufacturing costs, sufficient cash tracks, and collaborative transformation capabilities; Particle engineering or early safety alone are insufficient to support long-term value.
As of the time of writing, the U.S. FDA has not yet approved any exosome products and clearly states that exosome products used to treat diseases are typically drugs or biologics requiring premarket review. Unapproved cosmetic, anti-aging, or regenerative treatments offered under the name of “exosome therapy” on the market cannot be used as clinically validated evidence for drug platforms. Formal projects need to advance according to the logic of innovative biological products, completing source control, viral safety, impurity, efficacy, non-clinical distribution and toxicology, as well as clinical dosage exploration.

---

(5) Recent Developments and Transactions: Industry focus has shifted from proof of concept to tissue delivery and CMC

public progress in 2025–2026, indicating that the exosome sector has not stopped developing, but capital and partners are placing greater emphasis on verifiable tissue delivery, manufacturing feasibility, and clinical pathways.
On the clinical side, RION completed enrollment for Phase II diabetic foot ulcers; ILIAS published the first systematic delivery of allogeneic engineered EV Phase I results; Brexogen discloses mid-stage progress of Phase I atopic dermatitis.
On the platform side, Evox will launch the Rett syndrome gene editing delivery evaluation in 2026, and Turn Biotechnologies will acquire Vesigen’s ARMMs vesicle delivery technology in 2025 to expand tissue coverage of its mRNA epigenetic reprogramming therapy.
On the manufacturing side, more companies are addressing clinical supply issues in advance through master cell banks, GMP capacity, and specialized collaborations. For example, NurExone is advancing its U.S. manufacturing system, and Pandorum is collaborating with industrialization partners to expand exosome manufacturing capacity in the Asia-Pacific region in 2026.
Early large deals validated pharmaceutical companies’ demand for non-viral delivery. In 2020, Evox and Takeda reached a protein and mRNA delivery collaboration covering up to five rare disease targets, with a maximum potential public value of approximately $882 million; Codiak and Sarepta are also collaborating concurrently to explore gene therapy, gene editing, and RNA payloads. In 2021, Lonza acquired Codiak’s exosome manufacturing facility and built process development, purification, and analytical capabilities, demonstrating that clinical-grade CMCs can independently generate transaction value. Entering 2025–2026, the deal structure will lean more towards platform integration and targeted joint validation: Turn Biotechnologies will acquire Vesigen’s ARMMs vesicle technology in 2025 to expand tissue coverage of its mRNA epigenetic reprogramming therapies; In 2026, Evox will partner with the Rett Syndrome Research Trust to directly bind ExoEdit to specific diseases and gene editing tasks.
These developments indicate that market attention has shifted from “whether exosomes can serve as carriers” to “whether specific loads can produce repeatable pharmacological effects in specific tissues.” Platforms with collaborative value need to simultaneously address loading location and load integrity, intracellular release of targets, conjecture escape, dose-effect relationships, non-target tissue exposure, and scaling costs. Projects that can provide effective subgroup identification and enrichment techniques are especially noteworthy, as the total number of particles does not equal the number of effective particles; If surface markers, cargo content, and tissue philophilic can be correlated with potency, formulation consistency may be significantly improved and dose burden caused by ineffective particles reduced.

---

(6) Business logic: The transaction value of delivery platforms comes from a replicable combination of “payload × organizations

.” The commercial value of exosome platforms should not be measured solely by a single drug candidate. If the platform can adapt to multiple loads within the same production and engineering system and form verifiable delivery modules for different organizations, it may support multiple collaborative projects. Typical collaborations can start with a paid feasibility study, with the platform handling payload loading, in vitro function, and preliminary in vivo distribution; Upon reaching milestones, we proceed to exclusive target licensing or joint development. The transaction structure typically includes research funding, technology access fees, upfront payments, development and sales milestones, and revenue sharing, and may also split rights by target, indication, or region.
For large pharmaceutical companies, the appeal of platform collaboration lies in reducing the risks of new payload delivery and expanding extrahepatic tissue; For early-stage tech companies, external collaboration can provide loadloads, disease models, regulatory and funding resources. Whether the platform has the capability to license non-exclusive technologies is especially important: if the same underlying process can be reused across different targets and indications, and rights conflicts are avoided through fieldized intellectual property and project isolation, its revenue model is usually superior to that of a single product company. Conversely, if each load connected requires redeveloping the entire process, the platform’s scalability and valuation logic will be significantly weakened.

---

(7) Asset Screening Criteria: Which exosome delivery platforms have greater cooperation value

1. Cell production and exosome sources
controllable; the source of the production cells, donor, and genetic background should be clearly defined, with a stable cell bank, acceptable culture medium system, and continuous batch data. It is necessary to specify the methods of immortalization or engineering, potential tumorogenic risks, viral safety, and control of exogenous factors.
2. Load loading can quantify and maintain functional
In addition to loading rate, load per particle or per dose, free load removal, membrane integrity, release kinetics, and functional testing should also be provided. RNA projects should demonstrate that the sequence produces silencing or expression effects upon entering target cells, rather than merely proving colocalization with vesicles.
3. Targeting Advantage Evidence
in vivo should be compared with unmodified exosomes, engineered exosomes, and appropriate control vectors to demonstrate functional delivery advantages at the target tissue and target cell levels. For brain, lung, tumor, or other extrahepatic tissues, the route of administration, dosage, repeated dosing, and non-target tissue exposure must also be specified.
4. CMC and analytical systems can support scale-up
, requiring scalable upstream cultivation and downstream purification protocols, clarifying particle yield, purity, inter-batch consistency, key quality attributes, potency detection, and stability. Laboratory ultracentrifuge data cannot replace convertible GMP processes.
5. Intellectual Property Boundary Coverage Key
Aspects of the platform can be protected include cell lines produced, exosome engineered structures, loading selection or loading methods, targeted ligands, purification processes, formulations, and specific therapeutic applications. The buyer will focus on evaluating the tier of platform patents versus single-project patents, third-party background IP, material transfer restrictions, and the attribution of future improvement outcomes.

---

(8) Opportunities and Challenges: The core of the next stage of competition is clinical transferability

Opportunities for exosome delivery platforms stem from complex payloads and the growing demand for extrahepatic delivery. RNA, gene silencing, protein substitution, and gene editing all require more tissue-selective delivery tools; The biological origin, membrane composition, and engineerability of exosomes provide technical space that distinguishes them from viral vectors and synthetic nanoparticles. Different mother cell sources may also develop natural tissue philophilia, making the ability to “screen for suitable production cells” itself a platform capability.
The challenges are equally clear. Exosomes are highly complex and heterogeneous biological particles, and changes in their source, cultivation conditions, and purification processes can alter their composition and activity; Load loading efficiency, container escape, dose measurability, long-term safety, and commercial costs still need to be addressed. The field is also disrupted by unapproved consumer product marketing, and formal drug development must establish boundaries with clear mechanisms, reproducible CMCs, and rigorous clinical evidence.
Therefore, the projects with the greatest trading potential are not platforms that claim to be “natural, low immunogenicity, and barrier-crossing,” but rather a complete evidence chain that has already formed from “stable cell production—quantifiable loading—in vivo functional delivery—scalable processes—clear IP.” For Chinese teams with modular technologies in exosome production, RNA loading, targeted ligands, lyophilized formulations, or large-scale purification, priority access to overseas platform companies’ R&D systems through paid validation, joint development, or option-to-license can be achieved, and then further deepen licensing through in vivo PoC and CMC milestones.

---

Cooperation 

matchmaking include high-quality assets related to exosome loading technology, manufacturing processes, subgroup screening, or early functional validation!
We welcome founders, BD leaders, and project teamsto connect and recommend at any time to efficiently advance deal negotiations and implementation.

Contact person: Tang Huadong

Cooperation Email: huadong.tang@meritsandtree.com;

yuhan.zhang@meritsandtree.com
zehao.yue@meritsandtree.com

Tang Huadong

Partner at Zhide

Lawyer Tang Huadong is a partner at Beijing Zhide Law Firm. Before joining Zhide, Lawyer Tang Huadong worked for many years at China Patent Agency (Hong Kong) Co., Ltd. and Beijing King & Wood Mallesons. He also worked for a long time in patent examination at the National Intellectual Property Administration and earned the title of Associate Researcher. Lawyer Tang Huadong has over ten years of practical experience in the field of technology and legal services, leading a team of key members graduated from renowned domestic and international universities with a combined technical and legal background, providing clients with professional and efficient technical and intellectual property legal support for high-value patent asset structuring, investment and financing transactions, IPOs and listings, dispute resolution, and government compliance.

Lawyer Tang Huadong specializes in providing practical intellectual property protection solutions based on clients’ commercial objectives, including but not limited to patent strategy planning, patent mining, drafting and examination of patent application documents, patent due diligence, patent stability analysis, FTO freedom implementation legal opinions, patent infringement analysis, patent invalidity challenges, patent infringement litigation, trade secret protection, and the construction of intellectual property protection systems.

Lawyer Tang Huadong graduated from Tsinghua University with a PhD in Biochemistry and Molecular Biology, and also earned a Master of Laws degree from China University of Political Science and Law. He is a visiting scholar at the University of Notre Dame, a member of the Pharmaceutical Professional Committee of the China Patent Protection Association, a member of the Patent Law Committee of the Beijing Lawyers Association, a council member of the Tsinghua Healthy Chinese Returned Scholars Association, a council member of the Intellectual Property Subcommittee of the World Federation of Chinese Medicine Societies, a member of the South-South Cooperation Promotion Association of the Ministry of Foreign Affairs, and has been awarded the title of Chambers by the internationally authoritative legal rating agency Recognized in the 2026 annual ranking of intellectual property businesses, recognized by internationally renowned legal media CBLJ as the “A-list Legal Elite Legal Elite” in 2023, Minglutang-Client Choice (an outstanding lawyer recommended by the Medical Health and Life Sciences Industry Law Association), invited to lecture at Yihong Business School, Tsinghua Institute of Technology, Beike University, Beijing Administration of Traditional Chinese Medicine, and keynote speeches at conferences held by Tongxieyi, Yaozhi.com, Yaorongquan, DIA, and others.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: meritsip@meritsandtree.com

© 2025 MeritsIP. All Rights Reserved.